Early precise detection and intervention are crucial for controlling the progression of diabetic cataract and saving vision, with biomarkers playing a central role in this process. Ace Therapeutics provides diabetic cataract biomarker development services. Our services encompass a comprehensive process focused on screening specific molecular markers through high-throughput omics technologies (e.g., proteomics and metabolomics), extending from biological sample collection and preprocessing, candidate marker discovery, and multi-dimensional validation (cellular/animal models) to clinical translation applications.

Overview of Biomarkers in Diabetic Cataract

Biomarkers, serving as indicators of biomolecular changes during the onset and progression of diabetic cataract, hold significant potential for early diagnosis, disease monitoring, prognostic evaluation, and therapeutic target identification. Current research has identified multiple biomarkers associated with diabetic cataract.

• Metabolites: Altered levels of metabolites such as sorbitol and inositol in the lens can be used as early markers of metabolic disorders in the lens. Oxidative stress-related metabolites in blood or atrial fluid, such as malondialdehyde and 8-hydroxydeoxyguanosine, suggest the degree of oxidative stress damage.
• Cytokines and inflammatory mediators: Cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are elevated in the atrial fluid or serum of individuals with diabetic cataracts, reflecting the degree of inflammatory response, which is of great significance in monitoring the disease and determining the prognosis.
• Proteins: Lens-associated proteins such as lens protein modifications and altered aggregation states, as well as specific protein markers in serum, such as insulin-like growth factor binding protein 3 (IGFBP3), can assist in the diagnosis and assessment of the disease.

Fig. 1 Summary of differentially expressed proteins identified in biofluids of DR patients. (Youngblood, H. et al., 2019)

Our Diabetic Cataract Biomarker Development Services

As a professional preclinical contract research organization in the field of diabetes, we provide comprehensive and customized diabetic cataract biomarker development services based on our advanced technology platform and rich experience.

• Sample collection and processing

We support clients in developing diabetic cataract animal models and collecting biological specimens under strictly standardized operating procedures (SOPs) to ensure sample integrity and stability. Utilizing validated processing technologies, we enable targeted biomarker enrichment and purification.

• Biomarker screening and identification

We comprehensively screen potential biomarkers using a combination of metabolomics, proteomics and transcriptomics technologies. The results are validated and optimized through bioinformatics analysis and statistical methods to identify reliable biomarkers.

• Functional validation and mechanistic studies

We utilize cell biology and molecular biology to functionally validate the identified biomarkers. By deeply exploring their roles in the pathogenesis of diabetic cataract, we provide a theoretical basis for drug development and clinical application.

Our Advanced Technology Platforms

Our cutting-edge technology platforms support the needs of biomarker development.

• Highly sensitive mass spectrometry platform for accurate detection of low-abundance metabolites and proteins in biological samples.
• High-throughput gene sequencing technology allows in-depth analysis of changes in gene expression profiles.
• Advanced cell culture and functional validation technologies can clarify biomarker function and mechanism of action.

Ace Therapeutics empowers clients to achieve groundbreaking advances in diabetic cataract biomarker research through our specialized services. We deliver end-to-end solutions from foundational discovery to clinical application development, leveraging deep scientific expertise. Contact with us today to unlock potential collaborations and service opportunities.

References

1. Ting, D. S. W. et al. Biomarkers of diabetic retinopathy. Current diabetes reports. 16.12 (2016): 125
2. Youngblood, H. et al. Proteomic biomarkers of retinal inflammation in diabetic retinopathy. International journal of molecular sciences. 20.19 (2019): 4755.

• Diabetic Cataract Pathological Research Services
• Diabetic Cataract Drug Development Services
• Diabetic Cataract Diagnostic Assay Development Services

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators